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ABSTRACT 
Background: Sarcoidosis is a multisystemic disorder of unknown etiology, characterised by the 
presence of non-caseating granulomas in target organs. In ninety percent of cases, there is 
thoracic involvement. Fifty to seventy percent of pulmonary sarcoidosis patients will experience 
acute, self-limiting disease. For the subgroup of patients who develop persistent disease, no 
targeted therapy is currently available.  
Aim: To investigate the potential of the single nucleotide polymorphism (SNP), Toll-like 
receptor 3 Leu412Phe (TLR3 L412F; rs3775291), as a causative factor in the development of, 
and in disease persistence in pulmonary sarcoidosis. To investigate the functionality of TLR3 
L412F in vitro in primary human lung fibroblasts from pulmonary sarcoidosis patients. 
Methods: Cohorts of Irish sarcoidosis patients (n=228), healthy Irish controls (n = 263) and a 
secondary cohort of American sarcoidosis patients (n=123) were genotyped for TLR3 L412F. 
Additionally, the effect of TLR3 L412F in primary lung fibroblasts from pulmonary sarcoidosis 
patients was quantitated following TLR3 activation in the context of cytokine and type I 
interferon production, TLR3 expression, and apoptotic- and fibroproliferative-responses. 
Results: We report a significant association between TLR3 L412F and persistent clinical disease 
in two cohorts of Irish and American Caucasians with pulmonary sarcoidosis. Furthermore, 
activation of TLR3 in primary lung fibroblasts from 412F-homozygous pulmonary sarcoidosis 
patients resulted in reduced IFN-β and TLR3 expression, reduced apoptosis- and dysregulated 
fibroproliferative-responses compared with TLR3 wild-type patients. 
Conclusions: This study identifies defective TLR3 function as a previously unidentified factor in 
persistent clinical disease in pulmonary sarcoidosis and reveals TLR3 L412F as a candidate 
biomarker. 
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INTRODUCTION 
Sarcoidosis is a multi-systemic disorder of unknown cause which is characterised by the 
presence of non-caseating granulomas in target organs. Ninety percent of sarcoidosis cases have 
thoracic involvement (1, 2). The highest annual incidence of sarcoidosis has been observed in 
northern European countries (5 to 40 cases per 100,000 people) (3). Phenotypically, sarcoidosis 
follows either an acute or chronic course. Up to seventy percent of patients present with acute 
sarcoidosis and experience self-limiting disease which will resolve within 1-2 years (4). In 
contrast, thirty to fifty percent of patients will develop persistent pulmonary sarcoidosis for 
which no approved treatments are currently available and corticosteroid use is the standard, non-
specific treatment method (4).  
Although mechanisms underlying the development of sarcoidosis are currently unknown, 
it hypothesized to be caused by an aberrant host immune response to unknown environmental 
antigens in genetically predisposed individuals. A number of alterations in sarcoidosis patients’ 
immune responses has been reported including, an exaggerated Th1 response, increased Th17 
activity, attenuated regulatory T cell responses and oligoclonal expansion of CD4+ T cell 
responses, which is consistent with chronic antigenic stimulation (5-9).  
To date, no specific pathogen has been identified as a causative factor in sarcoidosis. 
Several studies have a role for mycobacterial or propionibacterial organisms in the pathogenesis 
of sarcoidosis. Specifically, a meta-analysis of studies carried out between 1980 and 2006 
demonstrated that 26% of all sarcoidosis tissues had evidence of mycobacterial nucleic acids 
(10). In the context of viral infection, seroepidemiological studies have demonstrated significant 
levels of antibodies to Epstein-Barr virus (EBV), rubella and parainfluenza 3 in sarcoidosis (11). 
However, no correlation could be made between viral antibody titre and stage of disease or 
activity (11).  
In this study, we investigated the role of defective TLR3 in the development of persistent 
clinical disease in pulmonary sarcoidosis. TLR3 has previously been shown to bind dsRNA from 
viruses, bacteria and helminths, respectively, in addition to mRNA released from necrotic cells 
(2, 12-15). Specifically, here we investigated the role of the TLR3 polymorphism, Leu412Phe 
(TLR3 Leu412Phe, L412F; rs3775291) as a causative factor in the development of and in disease 
persistence in pulmonary sarcoidosis, respectively. Previously, we identified a role for TLR3 
L412F in accelerated disease progression and increased risk of mortality in idiopathic pulmonary 
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fibrosis (IPF) (16). TLR3 L412F has also been implicated as a causative factor in a number of 
autoimmune and inflammatory diseases such as diabetes, systemic lupus erythematosus (SLE) 
and rheumatoid arthritis (17-19), as well as a variety of cancers (20-24). TLR3 L412F has also 
been demonstrated to have either a protective or pathogenic effect in viral infection (25, 26).    
In this study, we report a significant association between development of a persistent 
clinical phenotype in pulmonary sarcoidosis and the TLR3 L412F variant in cohorts of Irish and 
American Caucasians, respectively. Furthermore, activation of TLR3 in vitro in primary human 
lung fibroblasts from 412F-homozygous patients resulted in decreased TLR3 and IFN-β 
expression, reduced apoptosis and dysregulated proliferation, respectively, compared with 
fibroblasts from TLR3 wild-type patients. Our findings imply that defective TLR3 promotes a 
persistent disease phenotype in sarcoidosis and reveals TLR3 L412F as a candidate prognostic 
biomarker in this interstitial lung disease. 
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MATERIALS AND METHODS  
Study Subjects 
A cohort of Irish Caucasian pulmonary sarcoidosis patients (n=228; Table 1) was recruited from 
St Vincent’s University Hospital, Elm Park, Dublin 4 (SVUH).  A cohort of Irish Caucasian 
healthy volunteers (n = 263) was additionally
 
recruited as a control group. Genomic DNA was 
obtained from the American cohort of sarcoidosis patients attending the specialized Sarcoidosis 
Clinic at Johns Hopkins University School, Baltimore, MA, USA (n=123; Table 1).  
 
Diagnosis of pulmonary sarcoidosis and classification of persistent disease 
Irish and American pulmonary sarcoidosis patients were diagnosed at initial hospital presentation 
by the same physician (S.C.D. and D.R.M), respectively, and followed-up for at least 2 years 
(see Supplementary Methods). Patients at 2 years follow-up were classified as having either 
“persistent” disease or “non-persistent” disease based on a modification of a system previously 
described (2)(see Supplementary Methods).  
 
 
TLR3 L412F genotyping 
TLR3 L412F genotyping was carried out as described by us previously in a parallel study 
investigating the role of the TLR3 L412F in IPF (16)(see Supplementary Methods). 
 
Analysis of TLR3 L412F functionality in primary human lung fibroblasts from pulmonary 
sarcoidosis patients 
Primary fibroblast cell lines were isolated from lung biopsies of sarcoidosis patients (supplied by 
SVUH) and cultured as described previously (27) (see Supplementary Methods). Methodology 
pertaining to the analysis of the effects of TLR3 L412F on fibroblast-apoptosis, -proliferation and 
-cytokine/interferon production, respectively, is detailed in the Supplementary Methods 
section. 
 
Statistical analysis 
All statistical analyses were carried out using GraphPad Instat Software (GraphPad Software Inc. 
CA, USA). Statistical analyses of genotype and allele frequencies were performed using two-
tailed χ2 tests (3 x 2 χ2 tests for independence and trend, respectively, or 2 x 2 χ2 test where 
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appropriate) or 2 x 2 Fisher’s exact tests if the χ2 test was inappropriate. Forward, stepwise 
logistic regression analysis was carried out to obtain corrected P values for appropriate 
confounders. One-way analysis of variance (ANOVA) was used to test for statistical significance 
(two-tailed analysis) between experimental groups of three. Multiple comparisons between 
groups were then assessed using the Tukey-Kramer post-hoc test (for parametric analysis) or 
Dunn’s post-hoc test (for non-parametric analysis). Statistical significance was recorded at 
p<0.05.  
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RESULTS 
TLR3 L412F (rs3775291) is not associated with development of pulmonary sarcoidosis in 
Irish patients 
In this study, we tested for an association between TLR3 L412F and development of pulmonary 
sarcoidosis in an Irish case-control study of 263 control subjects and 228 sarcoidosis cases 
(Table 2). L412F genotype frequencies in the Irish control group and Irish sarcoidosis group 
were determined to be consistent with Hardy-Weinberg Equilibrium (HWE; controls: P=0.32; 
cases: P=0.72). No significant association was found between development of sarcoidosis and 
the L412F genotypes [P=0.6326; Odds ratio (OR) for 412F (Phe) carriers: 1.105 (95% C.I.: 
0.774-1.578); OR for Phe/Phe homozygotes (Phe/Phe): 0.801 (C.I.: 0.387-1.660); Table 2] or 
allele frequency [P=0.8942; OR: 1.003 (C.I.: 0.774-1.372); Table 2]. This indicates that the 
variant allele does not strongly promote development of the disease in an Irish sarcoidosis 
population.  
 
TLR3 L412F promotes a persistent clinical phenotype in Irish patients with pulmonary 
sarcoidosis  
We then tested for an association between TLR3 L412F and disease persistence in sarcoidosis. 
Patients were defined as having either “persistent” (n=104) or “non-persistent” (n=124) disease 
at 2 years post-diagnosis according to established criteria (2) (Table 2). We observed a 
significant association between development of a persistent disease phenotype in Irish 
sarcoidosis patients and 412F homozygosity [P=0.0095; OR for Phe/Phe homozygotes: 5.762 
(C.I.: 1.594-20.284)], Table 2) and F allele frequency [P=0.0166; OR: 1.713 (C.I.: 1.122-2.617); 
Table 2]. This suggests that TLR3 412F homozygosity may be a useful prognostic biomarker in 
sarcoidosis.  
 
TLR3 L412F is associated with disease persistence in American Caucasians with sarcoidosis 
To test for replication of the association between TLR3 L412F and disease persistence in Irish 
sarcoidosis patients, we carried out a validation study in an American cohort of sarcoidosis 
patients. We genotyped 123 genomic DNA samples from patients attending a tertiary referral 
centre for sarcoidosis (Table 1). We found a significant association between L412F 
heterozygosity [P=0.0432; OR for Phe carriers: 3.535 (C.I.: 1.246-10.029); Table 3) and F allele 
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frequency [P=0.0221; OR: 2.836 (C.I.: 1.129-7.122); Table 3], respectively, and development of 
persistent disease in the overall American population.  Further analysis of individual Caucasian 
American and African American cohorts revealed a significant association between disease 
persistence and 412F heterozygote genotype [P=0.0114, OR for Phe carriers: 4.4 (CI: 1.411-
13.717); Table 3] and allele frequency [P=0.0205, OR: 3.175 (C.I.: 1.207-8.351); Table 3], 
respectively, in Caucasian Americans but not African Americans.  
 
Primary lung fibroblasts from TLR3 L412F homozygote sarcoidosis patients produce 
reduced IL-8 and IFN-β, and have reduced TLR3 expression 
In order to elucidate the mechanisms underlying the association between development of 
persistent disease and TLR3 412F, we investigated TLR3 function in primary human fibroblasts 
from TLR3 412F wild-type (Leu/Leu) versus homozygous (Phe/Phe) sarcoidosis patients with a 
persistent disease phenotype. Following TLR3 activation by Poly(I:C) treatment, variant Phe/Phe 
fibroblasts had significantly reduced IL-8 production (Fig. 1A; NF-κB-readout) and IFN-β 
expression (Fig. 1B; IRF3-readout), respectively. These findings conferred with the authors who 
first described the polymorphism and who reported that it resulted in defective TLR3 function 
via reduced NF-κB and IRF3 signaling (28). In addition, following TLR3 activation by Poly(I:C) 
treatment, variant Phe/Phe fibroblasts also had blunted TLR3 mRNA expression compared with 
wild-type fibroblasts (Fig. 1C). We have also shown additionally using FACS that the 
upregulation of extracellular TLR3 following Poly(I:C) treatment on Phe/Phe primary lung 
fibroblasts was blunted compared with wild-type cells (Supplementary Fig. S1A). In contrast, 
levels of intracellular TLR3 expression on wild-type and Phe/Phe fibroblasts were comparable 
following Poly(I:C) treatment (Supplementary Fig. S1B).   
 
TLR3 L412F inhibits apoptosis and dysregulates proliferation in primary lung fibroblasts 
from homozygote sarcoidosis patients 
Here we assessed the induction of TLR3-induced apoptosis in Leu/Leu and Phe/Phe fibroblasts 
and found a significantly reduced ability of Phe/Phe fibroblasts to undergo late-phase apoptosis 
compared with wild-type cells (Fig. 2A, B). Furthermore, we also observed a decreased ability of 
Phe/Phe cells to reduce their proliferation in response to Poly(I:C) compared with Leu/Leu cells 
(Fig. 3A). Interestingly, a comparable level of reduction in fibroproliferation was observed 
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following treatment of primary human lung fibroblasts for 24 h with 1000 I.U./ml IFN-β in cells 
from Leu/Leu and Phe/Phe patients (Fig. 3B). This result suggests that the dysregulated 
fibroproliferation seen in TLR3 defective, Phe/Phe fibroblasts may be due to their reduced ability 
to produce IFN-β.  
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DISCUSSION 
In this study, we investigated the role of defective TLR3 in the pathogenesis of pulmonary 
sarcoidosis. Specifically, we investigated the role of the TLR3 polymorphism, TLR3 L412F 
(rs3775291), as a causative factor in the development of, and in disease persistence in pulmonary 
sarcoidosis, respectively. Previously, we identified a role for TLR3 L412F in accelerated disease 
progression and increased risk of mortality in idiopathic pulmonary fibrosis (IPF) (16). In this 
study, we established that TLR3 L412F was not associated with development of pulmonary 
sarcoidosis but was significantly associated with disease persistence. Irish patients who presented 
with sarcoidosis, and who were TLR3 412F-homozygous, were significantly more likely to 
develop persistent disease. Therefore, these findings suggest that TLR3 L412F plays a broader 
role in interstitial lung disease and that its pathogenic effects are not limited to IPF. 
In this study, the association between TLR3 L412F and disease persistence in Irish 
pulmonary sarcoidosis patients was validated in a modest-sized American cohort of patients, 
attending a tertiary referral centre. American pulmonary sarcoidosis patients who had one copy 
of the variant allele were almost five times more likely to develop persistent disease. 
Interestingly, there was also a significant association between disease persistence and race. When 
Caucasian American and African American populations were analysed individually, a significant 
association was found between the 412F allele and disease persistence in Caucasian Americans 
but not in African Americans. This may reflect specific genetic backgrounds in Caucasian 
Americans compared to African Americans which results in different spectrums of disease 
presentations in both populations. These novel results merit further investigation using larger 
cohort-size. 
Here, we also report that primary lung fibroblasts from TLR3 412F-homozygous 
pulmonary sarcoidosis patients had reduced IL-8, IFN-β and TLR3 production or expression, 
reduced fibroblast apoptosis and dysregulated fibroproliferative responses compared with cells 
from wild-type patients, following TLR3-activation. Our findings imply that defective TLR3 
promotes a persistent disease phenotype in sarcoidosis by dysregulating apoptotic and 
fibroproliferative processes via an IFN-β-dependent process. Thus, this study identifies defective 
TLR3 function as a previously undescribed factor in the development of persistent clinical 
disease in pulmonary sarcoidosis and reveals the TLR3 signaling pathway as a novel therapeutic 
target in its treatment. (see Supplementary Fig. S2 for schematic of proposed mechanism). The 
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strength of this study lies in its exploration of the role of the change in primary lung fibroblast 
function in disease persistence in pulmonary sarcoidosis patients, in the context of the TLR3 
L412F polymorphism. In this study, primary lung fibroblasts from three patients from each 
respective genotype were utilised (i.e. TLR3 Leu/Leu wild-type and TLR3 Phe/Phe homozygote 
patients). In future studies to investigate the role of TLR3 L412F further in the pathogenesis of 
persistent pulmonary sarcoidosis, and as a candidate prognostic marker, additional lung 
fibroblasts from wild-type and homozygote patients will be recruited.To date, no specific 
pathogen has been identified as a causative factor in sarcoidosis. Several studies have a role for 
mycobacterial or propionibacterial organisms in the pathogenesis of sarcoidosis. Previously, a 
human herpes 8 (HHV-8) open reading frame DNA was detected in a significantly higher 
proportions of sarcoid- compared with non-sarcoid lung tissue (29). However, the role of these 
viruses, and of EBV particularly, in the etiology of sarcoidosis remains speculative (11, 29).  
TLR3 was originally identified as an anti-viral receptor and was shown to bind viral dsRNA 
(12). More recently, the role for TLR3 in microbial infection has been expanded. TLR3 is now 
known to additionally bind dsRNA from bacteria and helminths (13, 14). It has also been shown 
to bind mRNA which has been released from necrotic cells during infection and inflammation 
(15). In this study, the defective function associated with the effects of TLR3 L412F in cells from 
412F-homozygous patients would provide a mechanism by which bacterial or viral infection 
could promote a persistent clinical phenotype in sarcoidosis. 
In this study, we also observed that reduced IFN-β expression or production is one of the 
mechanisms by which TLR3 L412F mediates its effects. In the context of IFN-β, this has been 
shown to directly induce apoptosis in cells following TLR3 activation in an autocrine manner 
(30). Interestingly, the addition of IFN-β to in vitro cultures of our 412F-homozygous cells in 
our study resulted in a restoration to a wild-type proliferative phenotype. With the current 
therapeutic use of IFN-β in a variety of cancers and autoimmune disorders, our data would 
support the therapeutic targeting of sarcoidosis patients exhibiting the 412F-homozygous 
genotype with IFN-β. Therefore, we suggest that treatment of 412F-homozygous sarcoidosis 
patients with persistent clinical disease with recombinant IFN-β may represent a novel treatment 
regimen. Other authors have reported the induction of IFN-α-induced sarcoidosis in a patient 
being treated for hepatitis C and the development of sarcoidosis in multiple sclerosis and 
myeloma patients, respectively, following recombinant IFN-β treatment (31-34). However, 
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previously, Charlier et al. examined a series of four patients with sarcoidosis, treated by IFN-α or 
IFN-β for viral hepatitis or multiple sclerosis. Interestingly, no recurrence or exacerbation of 
sarcoidosis had occurred at 4 years of follow-up. This study series suggests that type I IFNs do 
not exacerbate sarcoidosis in remission and this makes their use possible if indicated. However, 
their effect in persistent forms of the disease needs further evaluation (35). 
 Sarcoidosis can follow a variable clinical course.  Historically, it is well recognised that 
presentation with erythema nodosum and bilateral hilar adenopathy on chest radiograph has a 
better prognosis (15% risk of chronicity and progression) compared to presentation with bilateral 
chest radiograph infiltrates (40% chance of progression).  However, we are unable to stratify, 
with a high degree of accuracy, the prognosis of individual patients at presentation. This is a 
significant clinical unmet need in clinical practice and in clinical trials design. It would be of 
significant advantage in clinical trials if we could enrich patient recruitment favoring a more 
aggressive clinical phenotype.  This would offer the best opportunity of assessing whether 
specific, proposed therapies are clinically efficacious or not.  This study reveals TLR3 L412F as 
a candidate prognostic biomarker in pulmonary sarcoidosis.  
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TABLE 1.  Study Demographics for Irish and American Sarcoidosis Cohorts, and TLR3 L412F (rs3775291) Genotypes. 
                  
     Irish Sarcoidosis cases                         American Sarcoidosis Cases  
                  
No.      228                       123 
Sex, M/F               109/119                                          53/70 
Median age, year range                                       32 (16-66)                                             42 (18-72) 
 
                  
    Leu/Leu Leu/Phe Phe/Phe    Leu/Leu Leu/Phe Phe/Phe 
                  
No.        127      85       16         91       28        4 
Sex, M/F      53/74    48/37                    8/8                  37/54    13/15      3/1 
Median age, year range   30 (17-65)        32 (16-63)              36 (24-66)            42 (18-65)              44 (28-75)           35 (23-38) 
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TABLE 2. TLR3 L412F (rs3775291) Polymorphism Frequencies in Pulmonary Sarcoidosis:  Irish Case-Control and Disease Persistence Studies. 
                  
            
   Irish Case-Control Study          Irish Disease Persistence Study    
 
Status   Leu/Leu  Leu/Phe Phe/Phe           Status  Leu/Leu   Leu/Phe   Phe/Phe  
                  
         
Control Subjects      140      108       15   Persistent      52         39         13      
(n=263)      (0.53)      (0.41)                 (0.06)   (n=104)     (0.50)      (0.37)         (0.13) 
 
Irish Sarcoidosis      127       85        16   Non-       75         46            3  
Cases   (0.56)                (0.37)                 (0.07)   Persistent   (0.61)      (0.37)                    (0.02) 
(n=228)          (n=124) 
 
P  values         P  values 
Genotype   
a
0.6326        Genotype  
f
0.0095 
g
(0.0157) 
Trend   
b
0.8350       Trend  
h
0.0133 
Allele   
c
0.8942       Allele  
i
0.0166 
 
Odds ratio (95% C.I.)        Odds ratio (95% C.I.) 
Phe carrier   
d
1.105 (0.774-1.578)    Phe carrier   
j
1.531(0.904-2.592) 
Phe/Phe homozygote  
e
0.801 (0.387-1.660)    Phe/Phe homozygote  
k
5.762 (1.594-20.284)   
                   
Irish Case-Control Study: L412F genotype frequencies did not differ significantly between control subjects and sarcoidosis cases: 
a
χ2 test for independence (2 
d.f.) and 
b
χ2 test for trend (1 d.f.). Odds ratio (OR) and 95% confidence interval (C.I.) for 
d
Phe carriers (Leu/Phe and Phe/Phe) and 
e
Phe/Phe homozygotes. 
c
Allele frequencies did not differ significantly between subjects and cases [χ2 test: P=0.8942; OR: 1.003 (C.I.: 0.774-1.372)]. Irish Disease Persistence Study: a 
significant association was observed between TLR3 L412F and disease persistence in Irish sarcoidosis cases. L412F genotypes were compared using: 
f
χ2 test for 
independence and 
h
χ2 test for trend, respectively. 
g
Logistic regression analysis was performed to calculate the adjusted P value for the confounding factors: age 
at diagnosis, gender and erythema nodosum positivity. OR (C.I.) for  
j
Phe carriers and 
k
Phe/Phe homozygotes. 
i
Allele frequencies were compared using a χ2 test 
[OR: 1.713 (C.I.: 1.122-2.617)]. 
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TABLE 3. Replication study: TLR3 L412F (rs3775291) Genotype and Disease Persistence in American Pulmonary Sarcoidosis cases. 
                  
               
Status               Leu/Leu             Leu/Phe              Phe/Phe  
                   
     
Persistent       55              24             3  
(n=82)    (0.67)      (0.29)      (0.04)               
                       
Non-persistent         36                4             1              
(n=41)    (0.88)      (0.10)     (0.02) 
 
P values (All U.S. cases)       Odds ratio (95% C.I.; All U.S. cases) 
Genotype    
a
0.0432 
b
(0.0077)    Phe carrier   
e
3.535 (1.246-10.029) 
Trend    
c
0.0278     Phe/Phe homozygote  
f
1.519 (0.153-15.082) 
Allele    
d
0.0221   
 
P values (Ethnicity)  Caucasians (n=71)   African Americans (n=52) 
Genotype   
g
0.0114     
h
0.3070 
Allele    
i
0.0205      
j
0.3204 
      
Odds ratio (95% C.I.)  Caucasians    African Americans 
Phe carrier   
k
4.400 (1.411-13.717)   
l
4.761 (0.2466-91.939) 
Phe/Phe homozygote  
m
1.902 (0.188-19.290)   
n
4.761 (0.2466-91.939) 
                   
A significant association was detected between TLR3 L412F and disease persistence in an American cohort of sarcoidosis patients attending a tertiary referral 
centre. L412F genotypes were compared within the overall American (U.S.) cohort using: 
a
3x2 χ2 test for independence (2 d.f.) and 
c
3x2 χ2 test for trend (1 d.f.), 
respectively. OR (95% C.I.) for 
e
Phe carriers and 
f
Phe/Phe homozygotes in overall U.S. cohort. 
d
Allele frequencies were compared using a 2x2 Fisher’s Exact 
test (OR: 2.836;  95% CI: 1.129-7.122). 
b
Logistic regression analysis was performed to calculate the adjusted P value, using the confounding factors: age at 
diagnosis, gender and race. A significant risk of disease persistence was conferred by L412F genotype 
b
(P=0.0077). However, a significant risk of disease 
persistence was also conferred by Caucasian ancestry (p=0.0295) compared with African American ancestry. Therefore, further analysis was carried out for 
individual Caucasian and African American populations, respectively. A significant association was found between disease persistence and genotype in 
Caucasians but not African Americans: 
g, h
Genotype frequencies and 
 I, j
allele frequencies were compared using 2x2 Fisher’s Exact tests. OR (95% C.I.) for  
k, l
Phe 
carriers and 
m, n
Phe/Phe homozygotes for Caucasians and African Americans, respectively. 
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FIGURE LEGENDS 
Figure 1.  Effect of TLR3 L412F on TLR3-induced IL-8, IFN-β mRNA and TLR3 mRNA in 
Leu/Leu and Phe/Phe primary human lung fibroblasts from pulmonary sarcoidosis 
patients. TLR3 L412F attenuates Poly(I:C)-driven (A) IL-8 production, (B) IFN-β mRNA and 
(C) TLR3 mRNA expression in primary human lung fibroblasts from Phe/Phe sarcoidosis 
patients compared with Leu/Leu patients at 24h post-treatment, as quantitated by ELISA and 
QPCR analysis, respectively. (A-C) *p<0.05, **p<0.01, ***p<0.001: Poly(I:C) 100 µg/ml 
compared with Medium-only at 24h post-treatment. ++p<0.01: Poly(I:C) 100 µg/ml in 
fibroblasts from Phe/Phe (n=3) compared with Leu/Leu patients (n=3). Results shown are the 
mean ± S.E.M. of (B, C) three or (A) six replicates from a representative of (B) two or (A, C) 
three separate experiments. 
 
Figure 2.  Effect of TLR3 L412F on TLR3-induced apoptotic responses in Leu/Leu and 
Phe/Phe primary human lung fibroblasts from pulmonary sarcoidosis patients.  
A significant increase in Poly(I:C)-induced (A, B) late-phase apoptosis in Leu/Leu, but not 
Phe/Phe, fibroblasts following 24h treatment, as quantitated by Annexin V/Propidium Iodide 
staining using FACS analysis. (B) *p<0.05, Poly(I:C) 100 µg/ml compared with Medium-only. 
++p<0.01: Treatment with 100µg/ml Poly(I:C) in fibroblasts from Phe/Phe (n=3) compared with 
Leu/Leu (n=3) Results shown are the mean ± S.E.M. of (B) six or (A) five replicates from a 
representative of (A, B) three separate experiments. 
 
Figure 3.  Effect of TLR3 L412F on TLR3-induced proliferative responses in Leu/Leu and 
Phe/Phe primary human lung fibroblasts from pulmonary sarcoidosis patients.  
(A) Poly(I:C) treatment significantly reduces proliferation of Leu/Leu fibroblasts following 24h 
treatment with 1-100 µg/ml Poly(I:C), as quantitated using 
3
H-thymidine incorporation. The 
fold-decrease in Poly(I:C)-induced proliferation at 100 µg/ml at 24h is significantly more in 
Leu/Leu compared with Phe/Phe fibroblasts, as quantitated using 
3
H-thymidine incorporation. 
(B) Reconstitution of Phe/Phe cells with recombinant human IFN-β (1000 I.U./ml) leads to an 
equivalent reduction in cell proliferation in Leu/Leu and Phe/Phe cells. (A, B) *p<0.05, 
**p<0.01, ***p<0.001: Poly(I:C) 100 µg/ml compared with Medium-only. ++p<0.01: Treatment 
Downloaded from https://academic.oup.com/qjmed/advance-article-abstract/doi/10.1093/qjmed/hcx243/4725112
by University of Tasmania Library user
on 04 January 2018
with 100 µg/ml Poly(I:C) in fibroblasts from Phe/Phe (n=3) compared with Leu/Leu patients 
(n=3). Results shown are the mean ± S.E.M. of (B) six or (A) five replicates from a 
representative of (A, B) three separate experiments. 
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MATERIALS AND METHODS 
Diagnosis of pulmonary sarcoidosis in Irish and American cohorts 
All Irish and American patients were assessed at initial hospital presentation by the same 
physician, respectively (Ireland: S.C.D, SVUH; US: D.R.M., JHU) and followed up for at last 2 
years. A tissue diagnosis was obtained in 90% of patients via transbronchial / bronchial / skin / 
mediastinal or video assisted thoracoscopic (VATS) biopsies.  The remaining patients presented 
with a compatible clinical presentation, associated with supportive radiological and 
bronchoalveolar (BAL) findings (i.e. CD4/CD8 ratio > 3.5). Disease severity in sarcoidosis was 
assessed using chest radiographic staging. Chest radiographs (staged 0–IV,
 
i.e. normal to 
fibrosis), and/or high-resolution computed
 
tomography, determined the presence or absence of a 
pulmonary
 
infiltrate or fibrosis. All patients were classified at presentation on chest radiograph 
based on the Scadding staging system (1). Forced
 
expiratory volume in one second, forced vital 
capacity and transfer
 
factor were also measured at recruitment and expressed as % predicted,
 
according to international guidelines (2).  
 
Classification of persistent or non-persistent pulmonary sarcoidosis at 2 years post-
diagnosis 
Irish and American pulmonary sarcoidosis patients at 2 years follow-up were classified as having 
either “persistent” disease or “non-persistent” disease based on a modification of a system 
previously described (2).  Briefly, persistent disease at 2 years follow-up was defined as: (a) 
patients who were Scadding stage II or III on chest radiograph with associated abnormal 
pulmonary function parameters (FVC and/or total lung capacity and or transfer factor < 80% of 
predicted values), (b) Patients who were Scadding stage IV on chest radiograph, (c) patients who 
were prescribed corticosteroids. Corticosteroids were prescribed for patients exhibiting a 
significant deterioration in pulmonary physiological parameters (DLCO decrease > 15%) 
associated with radiographic progression (2).
 
 
Culturing of primary fibroblasts from lung biopsies from patients 
Primary fibroblast cell lines were isolated from lung biopsies of sarcoidosis patients (supplied by 
SVUH) as follows. Briefly, lung tissue was mechanically separated into single-cell
 
preparation 
and contaminating red blood cells (RBC) were lysed with hypotonic
 
buffer (150 mM NH4Cl, 10 
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mM NaHCO3, 1 mM EDTA) for 2 min at
 
4°C. The remaining cells were added to 175 ml tissue 
culture
 
flasks. These cells were grown at 37°C in a humidified CO2 incubator
 
and fed DMEM 
containing 1% (v/v) antibiotic-antimycotic and 15%
 
(v/v) FBS twice weekly.  All fibroblast cell 
lines were isolated by serial passaging (up to five times) until a >99% fibroblast population was 
determined using morphological and immunohistochemical staining as previously described, to 
ensure the relative absence of other contaminating cell types such as epithelial cells and 
myofibroblasts. For in vitro studies, all cell lines were used between passages 3 and 8.  
 
TLR3 L412F genotyping 
Genomic DNA was extracted from (i) anticoagulated whole blood collected
 
in EDTA from cases 
and controls and (ii) primary human lung fibroblasts from patients with pulmonary sarcoidosis, 
respectively, using Qiagen Genomic DNA extraction Kits (QIAGEN Ltd, Crawley, UK). 10 
ng/µl DNA samples were genotyped for TLR3 L412F using an Applied Biosciences Genotyping 
Assays at Medical Solutions Plc (Source BioScience, Nottingham, U.K.) according to 
manufacturer’s instructions and as described by us previously (3). 
 
Annexin V/Propidium Iodide Staining 
Primary human lung fibroblasts were plated out at 100,000 cells/wells in a 6-well plate 
overnight. Following treatment with 1-100 µg/ml Poly(I:C) for 24h, cells were harvested and 
were prepared for Annexin V/Propidium Iodide staining [Annexin V-FITC Apoptosis Detection 
Kit II (Calbiochem); Propidium Iodide (Merck Chemicals Ltd. Nottingham, U.K.)]  as described 
previously (4). Stained samples were analyzed by FACS (BD Facscan Flow Cytometer, BD 
Bioscience, Oxford, U.K.).  
 
Proliferation assays 
Primary human lung fibroblasts were plated out at 100,000 cells/well in a 24-well plate 
overnight. Cells were then treated for 24h with 1-100 µg/ml Poly(I:C). After 16h of this 
treatment, 0.5 µCi/well [
3
H] thymidine (Amersham Biosciences, Buckinghamshire, U.K.) was 
added for an additional 8 h of culture. Cells were then harvested and proliferation was assessed 
by [
3
H]thymidine incorporation as described previously (5). Fibroblasts were treated with 1000 
I.U./ml recombinant human IFN-β for 24h where described. 
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Determination of cytokine levels by ELISA 
Concentrations of IL-8 and RANTES were determined in cell supernatants by ELISA (DuoSet; 
R&D Systems, MN, USA) according to manufacturer’s instructions, as carried out previously 
(6).  
 
Quantification of IFN-β mRNA and TLR3 mRNA expression by quantitative real-time 
PCR (QPCR) 
For QPCR analysis, primary human lung fibroblasts were plated out at 100,000 cells/well in a 
24-well plate overnight. Cells were then treated for 24h with 0.1-10 µg/ml Poly(I:C) before 
harvesting. Three wells of a 24-well plate were pooled per sample for total RNA extraction per 
treatment using TRI REAGENT (Sigma) according to manufacturer’s instructions. First-strand 
cDNA synthesis and subsequent QPCR for IFN-β mRNA expression was performed (Stratagene 
MX3000P Real-Time PCR System; Stratagene, CA, USA) as described previously (5). 
 
Quantitation of intracellular and extracellular TLR3 protein expression on in primary 
pulmonary fibroblasts by flow cytometry analysis.  
TLR3 protein surface expression was examined by flow cytometry analysis using a Beckman 
Coulter Cyan™ADP flow cytometer. In brief, cells were cultured in 24 well culture plates and 
treated with incremental doses of poly(I:C) for 24 h. Cells were washed with sterile PBS and 
dissociated using 200 µl of Trypsin-EDTA at 37°C. DMEM was added to neutralise Trypsin-
EDTA. Two wells were pooled for an approximate total of 100,000 cells/ml. Cells were 
centrifuged at 1000rpm to pellet cells. The supernatant was discarded and the washing process 
was repeated twice more.  For extracellular TLR3 protein staining the cell pellet was suspended 
in binding buffer to an approximate final concentration of 1-5 x10
6
 cells/ml. This consisted of 
5% fetal calf serum solution in PBS at 4°C. Subsequently, 199 µl of cell suspension was 
transferred to a clean tube and add 1 µl TLR3 antibody labelled with FITC Mouse anti human 
(ab45053). Then samples were mixed gently and incubated for 20 min at room temperature. The 
cells were washed with 1X binding buffer and centrifuge at 1000 rpm to pellet the cells. The 
supernatant was discarded and cells were re-suspended gently in 300 µl and analysed by flow 
cytometry or fluorescence microscopy. Software utilised for analysis was Summit 4.3 (Daco). 
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FIGURE LEGENDS 
Figure S1.  Effect of TLR3 L412F on Poly(I:C) induced intracellular and extracellular 
TLR3 expression in Leu/Leu and Phe/Phe primary human lung fibroblasts from 
pulmonary sarcoidosis patients.  (A) A significant increase in Poly(I:C)-induced extracellular 
TLR3 expression was observed in Leu/Leu, but not Phe/Phe, fibroblasts following 24h treatment, 
as quantitated using FACS analysis. (B) Increased Poly(I:C)-induced intracellular TLR3 
expression in Leu/Leu and Phe/Phe fibroblasts following 24h treatment, as quantitated using 
FACS analysis and expressed as fold-increase in mean channel fluorescence (MCF) in treated 
cells compared with medium-only cells. **p<0.01, ***p<0.001: Poly(I:C) 10 and 100µg/ml 
compared with Medium-only, respectively. Results shown are the mean ± S.E.M. of three 
replicates from a representative of two separate experiments. 
 
Figure S2.  Schematic of the putative effects of the TLR3 L412F polymorphism in the 
pathogenesis of self-limiting and persistent pulmonary sarcoidosis via an-IFN-β dependent 
mechanism. The results from this study have led us to the hypothesis that when pulmonary 
sarcoidosis is caused in TLR3 L412F wild-type patients (TLR3
Leu/Leu
) by an unknown TLR3-
dependent antigen (e.g. viral or bacterial dsRNA, or mRNA released from necrotic cells during 
inflammatory damage), this leads to the activation of TLR3 and subsequent production of IFN-β, 
increased fibroapoptosis and decreased fibroproliferation, respectively. This stabilizes the 
fibroblast pool and results in a self-limiting pulmonary sarcoidosis in TLR3 L412F wild-type 
patients. In contrast, the induction of pulmonary sarcoidosis by an unknown TLR3-dependent 
antigen in TLR3 L412F defective patients (TLR3
Phe/Phe
) leads to significantly lower activation of 
the TLR3 signalling pathway, with a subsequent production of low levels of IFN-β production, a 
failure to induce fibroapoptosis and to reduce fibroproliferation, respectively. This results in the 
development of a persistent clinical phenotype in TLR3 L412F defective patients and progressive 
pulmonary sarcoidosis. 
  
Downloaded from https://academic.oup.com/qjmed/advance-article-abstract/doi/10.1093/qjmed/hcx243/4725112
by University of Tasmania Library user
on 04 January 2018
  
 
 
 
 
 
 
 
           Fig. S1 
Downloaded from https://academic.oup.com/qjmed/advance-article-abstract/doi/10.1093/qjmed/hcx243/4725112
by University of Tasmania Library user
on 04 January 2018
   
 
          
 
 
            Fig. S2
Downloaded from https://academic.oup.com/qjmed/advance-article-abstract/doi/10.1093/qjmed/hcx243/4725112
by University of Tasmania Library user
on 04 January 2018
   
REFERENCES 
1. Present DH, Siltzbach LE. Sarcoidosis among the Chinese and a review of the worldwide 
epidemiology of sarcoidosis. Am Rev Respir Dis. 1967;95(2):285-91. 
2. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the 
European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other 
Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS 
Executive Committee, February 1999. Am J Respir Crit Care Med. 1999;160(2):736-55. 
3. O'Dwyer DN, Armstrong ME, Trujillo G, Cooke G, Keane MP, Fallon PG, et al. The 
Toll-like receptor 3 L412F polymorphism and disease progression in idiopathic pulmonary 
fibrosis. Am J Respir Crit Care Med. 2013;188(12):1442-50. 
4. Salaun B, Coste I, Rissoan MC, Lebecque SJ, Renno T. TLR3 can directly trigger 
apoptosis in human cancer cells. J Immunol. 2006;176(8):4894-901. 
5. Armstrong ME, Gantier M, Li L, Chung WY, McCann A, Baugh JA, et al. Small 
interfering RNAs induce macrophage migration inhibitory factor production and proliferation in 
breast cancer cells via a double-stranded RNA-dependent protein kinase-dependent mechanism. 
J Immunol. 2008;180(11):7125-33. 
6. Armstrong ME, Lavelle EC, Loscher CE, Lynch MA, Mills KH. Proinflammatory 
responses in the murine brain after intranasal delivery of cholera toxin: implications for the use 
of AB toxins as adjuvants in intranasal vaccines. J Infect Dis. 2005;192(9):1628-33. 
 
Downloaded from https://academic.oup.com/qjmed/advance-article-abstract/doi/10.1093/qjmed/hcx243/4725112
by University of Tasmania Library user
on 04 January 2018View publication stats
